Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
Kaji FA, Martinez-Calle N, Bishton MJ, Figueroa R, Adlington J, O'Donoghue M, Smith S, Byrne P, Paine S, Sovani V, Auer D, James E, Bessell EM, Grainge MJ, Fox CP. Kaji FA, et al. Br J Haematol. 2021 Nov;195(4):561-570. doi: 10.1111/bjh.17747. Epub 2021 Aug 8. Br J Haematol. 2021. PMID: 34368948
First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N, Alfonso A, Rifón J, Herrero I, Errasti P, Rábago G, Merino J, Panizo Á, Pardo J, Prósper F, García-Muñoz R, Lecumberri R, Panizo C. Martínez-Calle N, et al. Eur J Haematol. 2017 Jan;98(1):38-43. doi: 10.1111/ejh.12782. Epub 2016 Jun 28. Eur J Haematol. 2017. PMID: 27232286
Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP. Martínez-Calle N, et al. Br J Haematol. 2019 Mar;184(6):957-968. doi: 10.1111/bjh.15722. Epub 2018 Dec 13. Br J Haematol. 2019. PMID: 30548597 Free article.
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24. Br J Haematol. 2019. PMID: 31020646 Free article. No abstract available.
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR. Eyre TA, et al. Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20. Br J Haematol. 2019. PMID: 31222719 Free article.
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J, Yallop D, De Marco B, Krampera M, Trefz S, Orsucci L, Fabbri A, Illerhaus G, Cwynarski K, Ferreri AJM. Schorb E, et al. Br J Haematol. 2020 Jun;189(5):879-887. doi: 10.1111/bjh.16451. Epub 2020 Jan 29. Br J Haematol. 2020. PMID: 31997308 Free article.
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
López-Díaz de Cerio A, García-Muñoz R, Pena E, Panizo Á, Feliu J, Giraldo P, Rodríguez-Calvillo M, Martínez-Calle N, Grande C, Olave MT, Andrade-Campos M, Bandrés E, Núñez-Córdoba JM, Inogés S, Panizo C. López-Díaz de Cerio A, et al. Br J Haematol. 2020 Jun;189(6):1064-1073. doi: 10.1111/bjh.16474. Epub 2020 Mar 4. Br J Haematol. 2020. PMID: 32130737 Free article. Clinical Trial.
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N, Poynton E, Alchawaf A, Kassam S, Horan M, Rafferty M, Kelsey P, Scott G, Culligan DJ, Buckley H, Lim YJ, Ngu L, McCulloch R, Rowntree C, Wright J, McKay P, Fourali S, Eyre TA, Smith J, Osborne W, Yallop D, Linton K, Fox CP, Cwynarski K. Martinez-Calle N, et al. Br J Haematol. 2020 Aug;190(3):394-404. doi: 10.1111/bjh.16592. Epub 2020 Mar 31. Br J Haematol. 2020. PMID: 32232989 Free article.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, Cwynarski K, McKay P. Wilson MR, et al. Blood Adv. 2020 Aug 11;4(15):3586-3593. doi: 10.1182/bloodadvances.2020002421. Blood Adv. 2020. PMID: 32761231 Free PMC article.
51 results